In vitro activity of ofloxacin against Mycobacterium tuberculosis

Journal of the Formosan Medical Association

Volumn 96, Issue 1, 1997, Pages 13-16

  Yu, Ming Chih ^a   Suo, Jen ^a   Lin, Tao Ping ^a   Luh, Kwen Tay ^b  

^a CENTER FOR DISEASE CONTROL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

multidrug resistance; Mycobacterium tuberculosis; ofloxacin; Taiwan

Indexed keywords

AMINOSALICYLIC ACID; ETHAMBUTOL; ISONIAZID; KANAMYCIN; OFLOXACIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ARTICLE; DRUG ACTIVITY; HUMAN; IN VITRO STUDY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; TAIWAN; TUBERCULOSIS;

ANTI-INFECTIVE AGENTS; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN;

EID: 0031058451     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. American Thoracic Society: Treatment of tuberculosis and tuberculosis infection in adults and children. Am Rev Respir Dis 1994;149:1359-74.
2. British Thoracic Society: Chemotherapy and management of tuberculosis in the United Kingdom: recommendations of the Joint Tuberculosis Committee of the British Thoracic Society. Thorax 1990;45:403-8.
3. International Union Against Tuberculosis and Lung Disease: Antituberculosis regimens of chemotherapy: recommendations from the Committee on treatment of the International Union Against Tuberculosis and Lung Disease. Bull IUATLD 1988;63:60-4.
4. Department of Health, The Executive Yuan ROC: Health and Vital Statistics - 1. General Health Statistics 1994, Republic of China. Taipei: 1995:476-84.
5. Goble M, Iseman MD, Madsen LA, et al: Treatmentof 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. New Engl J Med 1993;328:527-32.
6. Bates JH: Tuberculosis chemotherapy: the need for new antituberculosis drugs is urgent. Am J Respir Crit Care Med 1995;151:942-3.
7. Tsukamura M: In vitro antituberculosis activity of a new antibacterial substance ofloxacin (DL8280). Am Rev Respir Dis 1985;131:348-51.
8. Heifets LB, Lindholm-Levy PJ: Bacteriostatic and bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Tubercle 1987;68:267-76.
9. Young LS, Berlin OGW, Inderlied CB: Activity of ciprofloxacin and other fluorinated quinolones against mycobacteria. Am J Med 1987;82(suppl 4A):23-6.
10. Texier-Maugein J, Mormede M, Fourche J: In vitro activity of new fluoroquinolones against eighty-six isolates of mycobacteria. Eur J Clin Microbiol Infect Dis 1987;6:584-6.
11. Leysen DC, Haemers A, Pattyn SR: Minireview: mycobacteria and the new quinolones. J Antimicrob Chemother 1989;33:1-4.
12. Tsukamura M, Nakamura E, Yoshii S, et al: Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis. Am Rev Respir Dis 1985;131:352-6.
13. Hong Kong Chest Service/British Medical Research Council: A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Tuberc Lung Dis 1992;73:59-67.
14. Kohno S, Koga H, Kaku M, et al: Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis. Chest 1992;102:1815-8.
15. Chen CH, Shih JF, Lindholm-Levy PJ, et al: Minimal inhibitory concentrations of rifabutin, ciprofloxacin, and ofloxacin against Mycobacterium tuberculosis isolated before treatment of patients in Taiwan. Am Rev Respir Dis 1989;140:987-9.
16. Suo J, Hsieh CD, Lin TP: Ofloxacin in the treatment of multiple drug resistant tuberculosis (abstract). Thorac Med 1994;9(suppl):39.
17. Canetti G, Froman S, Grosset J, et al: Mycobacteria: laboratory methods for testing drug sensitivity and resistance. Bull WHO 1963;29:565-78.
18. Heifets LB: Antituberculosis drugs: antimicrobial activity in vitro. In: Heifets LB. Drug Susceptibility in the Chemotherapy of Mycobacterial Infections. Boca Raton: CRC Press, 1991:27-8.
19. Todd PA, Faulds D: Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology and therapeutic use. Drugs 1991;42:825-76.
20. Perea EJ: Ofloxacin concentrations in tissues involved in respiratory tract infections. J Antimicrob Chemother 1990;26 (suppl D):55-60.
21. Crewel AJ, Elkins N, May MH: Effectiveness of ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium, and rifampin against M. tuberculosis in cultured human macrophages. Am Rev Respir Dis 1988;137:1141-6.
22. Berning SE, Madsen L, Iseman MD: Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections. Am J Respir Crit Care Med 1995;151:2006-9.
23. Yew WW, Kwan SYL, Ma WK, et al: In vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiple resistant pulmonary tuberculosis. J Antimicrob Chemother 1990;26:227-36.
24. Iseman MD: Treatment of multidrug-resistant tuberculosis. New Engl J Med 1993;329:784-91.
25. Nakae I, Nakatani K, Inoue S, et al: Therapeutic effect of ofloxacin on intractable pulmonary tuberculosis and ofloxacin resistance of tubercle bacilli isolated from the patient. Kekkaku 1991;66:299-307.